About Us
| Download Documents | |
| COMPANY FACT SHEET | |
| ADC SOLUTIONS | |
| OTHER CONJUGATES SOLUTIONS | |
| AqT™ REAGENT & PRODUCT | |
| AqT™ Therapeutics Flyer |
CellMosaic®, Inc. is an innovator and leader in bioconjugation and crosslinking technologies.
The company was established in 2008 by Dr. Huang, a technological entrepreneur with profound interest and experience in the conjugation field. Dr. Huang has a PhD in Chemistry from CWRU in Cleveland and received postdoctoral training in biology under Nobel Laureate H. Gobind Khorana from MIT.
Since 2008, CellMosaic® has spent a lot of research effort on developing advanced conjugation processes that involve controlled, site-specific, or single labeling methods. These processes can generate single ratio conjugates with greater than 90% purity. We have built a successful custom conjugation service business based on these processes and delivered more than 500 projects and 300 unique conjugates (as of March 2023) for our customers covering a variety of compounds, including proteins, antibodies, peptides, oligos, enzymes, and chemotherapeutic agents. Most of the conjugation methods and technique know-how are protected as trade secrets. For details regarding our custom conjugation services, please visit our products and services.
Recently, we started to commercialize personalized™ conjugation kits (PerKit™) based on these conjugation processes. Customers can use these kits in house to prepare conjugates with similar high quality as we do at CellMosaic. For chemicals and conjugates used frequently by customers, we commercialize them as a product at a lower price due to the scale of the economy. For details regarding CellMosaic's PerKit™ and related products, please visit our products and services page.
Over the years, CellMosaic® has also pioneered the concept of utilizing sugar alcohol (SA) monomers to chemically assemble a new type of crosslinking reagents and polymer carriers, called AqueaTether™ (AqT™), for conjugation and drug delivery. SA is structurally analogous to polyethylene glycol (PEG), but has many advantages over PEG in terms of a) hydrophilicity, b) loading, c) versatility, and d) easy customization. AqT™ linkers/polymers are by far the most versatile molecules in development. Several other key technologies have also been developed at CellMosaic®, including oxLink™ and sxLink™ technologies for studying protein–protein interactions, and NeIon™ technologies for detecting and quantitating trace amounts of analytes of interest by Mass Spectrometry. Currently, we are developing products using these technologies for R&D usage. For details regarding our technologies, please visit our technologies page.
One of the main goals of developing AqT™ linkers and polymers is for drug conjugation and delivery. Please visit www.aqttherapeutics.com to learn more about these applications. Customers who wish to develop their own proprietary therapeutics based on AqT linkers and polymers are encouraged to contact us for how to access these technologies.